Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,167 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pediatric Tumors Clear all
Completed Phase 1Phase 2 Interventional

Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia

NCT01842672
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma/Leukemia
Interventions
Clofarabine, Mitoxantrone
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Up to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Valhalla, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 26, 2026, 2:03 PM EDT
Completed Phase 1 Interventional

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

NCT00436657
View directory record Official record
Conditions
Peritoneal Neoplasms, Retroperitoneal Neoplasms, Gastrointestinal Neoplasms, Adenocarcinoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Adrenocortical Carcinoma, Wilms Tumor, Rhabdomyosarcoma, Desmoplastic Small Round Cell Tumor
Interventions
CHPP of Cisplatin, Abdominal Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Oct 26, 2026, 2:03 PM EDT
Terminated Phase 1 Interventional

9-ING-41 in Pediatric Patients With Refractory Malignancies.

NCT04239092
View directory record Official record
Conditions
Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
Interventions
9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
Up to 22 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
9
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 26, 2026, 2:03 PM EDT
Active, not recruiting Phase 3 Interventional

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

NCT03020030
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
Pegaspargase, Erwinia asparaginase, Cyclophosphamide, CYTARABINE, DASATINIB, DEXAMETHASONE, Dexrazoxane, Doxorubicin, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, NELARABINE, Vincristine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2034
U.S. locations
7
States / cities
Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 26, 2026, 2:03 PM EDT
Completed No phase listed Observational

Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture

NCT02355340
View directory record Official record
Conditions
Bone Mineral Density, Childhood Cancer Survivors
Interventions
Dual energy x-ray absorptiometry (DXA), Peripheral quantitative computed tomography (pQCT)
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
8 Years to 20 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 26, 2026, 2:03 PM EDT
Recruiting Phase 1 Interventional

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

NCT04185038
View directory record Official record
Conditions
Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma, Medulloblastoma, Childhood, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma, Childhood, Glioma
Interventions
SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 26 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2042
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 26, 2026, 2:03 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774
View directory record Official record
Conditions
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
Interventions
Tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 2:03 PM EDT
Completed Phase 4 Interventional

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

NCT00230217
View directory record Official record
Conditions
Tumors, Hyperuricemia, Tumor Lysis Syndrome
Interventions
Rasburicase (SR29142)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Berkley, California • Denver, Colorado • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2009 · Synced Oct 26, 2026, 2:03 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

QPlus Pediatric Reference Interval

NCT05645133
View directory record Official record
Conditions
Pediatric ALL, Healthy
Interventions
Diagnostic Test
Device
Lead sponsor
HemoSonics LLC
Industry
Eligibility
Up to 17 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 26, 2026, 2:03 PM EDT
Completed Not applicable Interventional

SurvivorLink: Scalability of an Electronic Personal Health Record

NCT03543852
View directory record Official record
Conditions
Childhood Cancer
Interventions
SurvivorLink
Behavioral
Lead sponsor
Emory University
Other
Eligibility
15 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 26, 2026, 2:03 PM EDT
Completed Phase 2 Interventional

A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients

NCT00042328
View directory record Official record
Conditions
Neoplasms
Interventions
Valacyclovir
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 26, 2026, 2:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

NCT00372619
View directory record Official record
Conditions
Leukemia
Interventions
clofarabine, cytarabine, methotrexate, laboratory biomarker analysis
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
74
States / cities
Birmingham, Alabama • Downey, California • Long Beach, California + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 26, 2026, 2:03 PM EDT
Recruiting Phase 1 Interventional

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

NCT04897321
View directory record Official record
Conditions
Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical Cancer, Desmoplastic Small Round Cell Tumor, Germ Cell Cancer, Rhabdoid Tumor, Clear Cell Sarcoma, Hepatoblastoma, Melanoma, Carcinoma, Malignant Peripheral Nerve Sheath Tumors, Soft Tissue Sarcoma
Interventions
Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 26, 2026, 2:03 PM EDT
Completed Phase 1 Interventional

Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma

NCT00258687
View directory record Official record
Conditions
Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Renal Cell Carcinoma, Melanoma
Interventions
GVAX
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 26, 2026, 2:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment and Rehabilitation of Cognitive Impairments in Pediatric Survivors of Cancer

NCT00490334
View directory record Official record
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
9 Years to 16 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 26, 2026, 2:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Durvalumab and Tremelimumab for Pediatric Malignancies

NCT03837899
View directory record Official record
Conditions
Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
Interventions
Durvalumab / Tremelimumab Combination Therapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 26, 2026, 2:03 PM EDT
Terminated Phase 1 Interventional

RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

NCT04525014
View directory record Official record
Conditions
Brain Tumor, Recurrent, Brain Tumor, Pediatric, Central Nervous System Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
RRx-001, Temozolomide, Irinotecan
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
1 Year to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 26, 2026, 2:03 PM EDT
Completed Phase 1 Interventional Results available

High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma

NCT01313936
View directory record Official record
Conditions
Neuroblastoma
Interventions
Metaiodobenzylguanidine (MIBG)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 30 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 26, 2026, 2:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

NCT05071209
View directory record Official record
Conditions
Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
Interventions
Elimusertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 30 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 26, 2026, 2:03 PM EDT
Terminated No phase listed Observational

Relationship Between EBV and PTLD

NCT00215033
View directory record Official record
Conditions
Pediatric Heart Transplant
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 26, 2026, 2:03 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Study of Brain Tumors (Tectal Tumors) Using Magnetic Resonance Imaging

NCT00229814
View directory record Official record
Conditions
Tectal Plate Glioma
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
4 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 26, 2026, 2:03 PM EDT
Terminated Phase 1 Interventional

A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis

NCT02057289
View directory record Official record
Conditions
Immunocompromised, Bone Marrow Transplant, Cancer
Interventions
Micafungin
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 26, 2026, 2:03 PM EDT
Recruiting Not applicable Interventional

Serial MRI Scans During Radiation Therapy

NCT04188535
View directory record Official record
Conditions
Glioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging, MRI, Prostate Cancer, Vulvar Cancer, Pediatric Glioblastoma Multiforme, Sarcoma
Interventions
MRI IMAGING
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 26, 2026, 2:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States

NCT01211990
View directory record Official record
Conditions
Cancer, Allogeneic Peripheral Blood Stem Cell Transplant, Bone Marrow Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 26, 2026, 2:03 PM EDT